ATE421535T1 - Peg-modifiziertes erythropoietin - Google Patents
Peg-modifiziertes erythropoietinInfo
- Publication number
- ATE421535T1 ATE421535T1 AT01970285T AT01970285T ATE421535T1 AT E421535 T1 ATE421535 T1 AT E421535T1 AT 01970285 T AT01970285 T AT 01970285T AT 01970285 T AT01970285 T AT 01970285T AT E421535 T1 ATE421535 T1 AT E421535T1
- Authority
- AT
- Austria
- Prior art keywords
- peg
- epo
- conjugated
- native
- erythropoietin
- Prior art date
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 8
- 229920001223 polyethylene glycol Polymers 0.000 abstract 6
- 102100031939 Erythropoietin Human genes 0.000 abstract 5
- 230000002459 sustained effect Effects 0.000 abstract 3
- 102000003951 Erythropoietin Human genes 0.000 abstract 2
- 108090000394 Erythropoietin Proteins 0.000 abstract 2
- 229940105423 erythropoietin Drugs 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000315421 | 2000-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE421535T1 true ATE421535T1 (de) | 2009-02-15 |
Family
ID=18794529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01970285T ATE421535T1 (de) | 2000-10-16 | 2001-09-28 | Peg-modifiziertes erythropoietin |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20040082765A1 (de) |
| EP (1) | EP1333036B1 (de) |
| JP (1) | JP5170931B2 (de) |
| AT (1) | ATE421535T1 (de) |
| AU (1) | AU2001290312A1 (de) |
| DE (1) | DE60137525D1 (de) |
| ES (1) | ES2320101T3 (de) |
| WO (1) | WO2002032957A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5207590B2 (ja) * | 2002-12-26 | 2013-06-12 | マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド | 増強された生物学的能力を有するインターフェロン−βのポリマー結合体 |
| US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| US7314859B2 (en) | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| EP1471153A3 (de) * | 2003-03-21 | 2005-06-15 | F. Hoffmann-La Roche Ag | Transkriptionsaktivitätsassay |
| CA2458085A1 (en) | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
| CA2527665A1 (en) * | 2003-05-30 | 2004-12-16 | Centocor, Inc. | Formation of novel erythropoietin conjugates using transglutaminase |
| WO2005058366A2 (en) * | 2003-12-10 | 2005-06-30 | Nektar Therapeutics Al, Corporation | Compositions comprising two different populations of polymer-active agent conjugates |
| ATE469654T1 (de) * | 2003-12-30 | 2010-06-15 | Augustinus Bader | Verwendung des erythropoietins zur regeneration von lebergewebe |
| US7714114B2 (en) | 2005-02-16 | 2010-05-11 | Nektar Therapeutics | Conjugates of an EPO moiety and a polymer |
| WO2006135930A2 (en) * | 2005-06-13 | 2006-12-21 | Nastech Pharmaceutical Company Inc. | Transmucosal delivery of peptide derivatives |
| IL169377A (en) | 2005-06-23 | 2012-09-24 | Avigdor Shafferman | Uniformly conjugated serine hydrolases |
| EP1929860A4 (de) * | 2005-08-31 | 2010-12-29 | Kaneka Corp | Transgener vogel mit fremdgen enthaltend eine sequenz, die für ein von der katze abstammendes protein codiert, sowie verfahren zu seiner herstellung |
| US20080171696A1 (en) * | 2005-10-21 | 2008-07-17 | Avigenics, Inc. | Pharmacodynamically enhanced therapeutic proteins |
| CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| AU2007245190B2 (en) * | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
| US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| US8299015B2 (en) | 2006-07-25 | 2012-10-30 | Lipoxen Technologies Limited | Derivatisation of granulocyte colony-stimulating factor |
| GB0615067D0 (en) * | 2006-07-28 | 2006-09-06 | Ttp Communications Ltd | Reconfigurable signal processing scheme |
| PL2054074T3 (pl) * | 2006-08-04 | 2015-03-31 | Prolong Pharmaceuticals Llc | Zmodyfikowana erytropoetyna |
| PT2101821E (pt) | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
| JP5514736B2 (ja) | 2008-01-11 | 2014-06-04 | セリナ・セラピユーテイツクス・インコーポレーテツド | ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物 |
| US8101706B2 (en) | 2008-01-11 | 2012-01-24 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
| GB0922354D0 (en) | 2009-12-21 | 2010-02-03 | Polytherics Ltd | Novel polymer conjugates |
| PT2432489T (pt) | 2009-05-20 | 2016-12-07 | Biomarin Pharm Inc | Variantes do péptido natriurético de tipo c |
| CA2773596C (en) * | 2009-09-15 | 2017-11-28 | Kaneka Corporation | Modified erythropoietin to which water-soluble long-chain molecule is added |
| WO2015130963A2 (en) | 2014-02-27 | 2015-09-03 | Xenetic Biosciences, Inc. | Compositions and methods for administering insulin or insulin-like protein to the brain |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US5100664A (en) * | 1985-09-20 | 1992-03-31 | Cetus Corporation | Human IL-2 as a vaccine adjuvant |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| JP2502646B2 (ja) | 1988-01-19 | 1996-05-29 | 松下電器産業株式会社 | バ―ナ |
| JPH029900A (ja) * | 1988-04-12 | 1990-01-12 | Kirin Amgen Inc | 修飾エリスロポエチン |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| FI935485L (fi) * | 1992-12-09 | 1994-06-10 | Ortho Pharma Corp | PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| EP0816381B1 (de) * | 1995-03-10 | 2004-01-14 | NAKAMURA, Toshikazu | Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol |
| US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| EP0964702B1 (de) * | 1996-08-02 | 2006-10-04 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer |
| WO1998032466A1 (en) * | 1997-01-29 | 1998-07-30 | Polymasc Pharmaceuticals Plc | Pegylation process |
| ES2297889T3 (es) * | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| EP1135493A2 (de) * | 1998-11-30 | 2001-09-26 | Eli Lilly And Company | Erythropoietische substanzen |
| CA2359345A1 (en) * | 1999-01-14 | 2000-07-20 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| IL144361A0 (en) | 1999-01-29 | 2002-05-23 | Hoffmann La Roche | Gcsf conjugates |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
-
2001
- 2001-09-28 WO PCT/JP2001/008539 patent/WO2002032957A1/ja not_active Ceased
- 2001-09-28 ES ES01970285T patent/ES2320101T3/es not_active Expired - Lifetime
- 2001-09-28 EP EP01970285A patent/EP1333036B1/de not_active Expired - Lifetime
- 2001-09-28 JP JP2002536338A patent/JP5170931B2/ja not_active Expired - Lifetime
- 2001-09-28 US US10/399,254 patent/US20040082765A1/en not_active Abandoned
- 2001-09-28 AT AT01970285T patent/ATE421535T1/de active
- 2001-09-28 DE DE60137525T patent/DE60137525D1/de not_active Expired - Lifetime
- 2001-09-28 AU AU2001290312A patent/AU2001290312A1/en not_active Abandoned
-
2006
- 2006-08-03 US US11/498,053 patent/US8022191B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1333036A1 (de) | 2003-08-06 |
| EP1333036B1 (de) | 2009-01-21 |
| US20060276634A1 (en) | 2006-12-07 |
| JPWO2002032957A1 (ja) | 2004-02-26 |
| DE60137525D1 (de) | 2009-03-12 |
| ES2320101T3 (es) | 2009-05-19 |
| AU2001290312A1 (en) | 2002-04-29 |
| US20040082765A1 (en) | 2004-04-29 |
| US8022191B2 (en) | 2011-09-20 |
| WO2002032957A1 (en) | 2002-04-25 |
| JP5170931B2 (ja) | 2013-03-27 |
| EP1333036A4 (de) | 2004-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60137525D1 (de) | Peg-modifiziertes erythropoietin | |
| LU92175I2 (fr) | Lixisénatide | |
| ATE463260T1 (de) | Ortspezifische duale pegylation von proteine | |
| ATE364654T1 (de) | Polyamideketten von genauer länge und deren konjugate mit proteinen | |
| AU2001296962A1 (en) | Pegylated interleukin-10 | |
| ATE550041T1 (de) | Transglutaminase-vermittelte konjugation von peptiden | |
| ATE89743T1 (de) | Conjugate dichter sterne. | |
| EA200100838A1 (ru) | Конъюгаты гксф | |
| DK0510356T3 (da) | Polyethylenglycolproteinkonjugater | |
| DE60321825D1 (de) | Maleinsäureamid polymerderivate und ihre biokonjugate | |
| DK0973819T3 (da) | Ikke-antigene forgrenede polymerkonjugater | |
| DK1274728T3 (da) | Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi | |
| ATE505204T1 (de) | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) | |
| UY24572A1 (es) | Conjugados peg - interferon alfa | |
| WO2006081249A8 (en) | Conjugates of biologically active proteins having a modified in vivo half-life | |
| ATE88898T1 (de) | Cd4-polypeptidderivate. | |
| DE69432141D1 (de) | Taxane mit furyl-oder thienyl substituierten seitenketten | |
| DE60236796D1 (de) | Verzweigte polyalkylenglykole | |
| EP1809661A4 (de) | Humanes interferon-beta-mutein | |
| DK0557199T3 (da) | Polyethylenglycol-hirudin-konjugater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af tromboser | |
| WO2005090395A3 (en) | Methods for increasing protein polyethylene glycol (peg) conjugation | |
| CA2373252A1 (en) | Long lasting anti-angiogenic peptides | |
| TR200200599T2 (tr) | İnsan insülini monomerik analogları. | |
| WO2004043884A3 (en) | Novel acylating reagents | |
| TH52654A (th) | แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1333036 Country of ref document: EP |